PharmaFluidics Facilitates Ultra-High-Resolution Proteomics Analysis Through Agreement With Thermo Fisher Scientific

Monday, October 1, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

The agreement will allow bio-analysis customers to simplify workflows and improve the analytical performance of their HPLC-MS systems

GHENT, Belgium, October 1, 2018 /PRNewswire/ --

PharmaFluidics NV, an innovative bio-analytical chromatography company, announced today that it entered into a Partnership Agreement with Thermo Fisher Scientific Inc, a global Life Sciences Tools and Instruments leader. The agreement empowers PharmaFluidics to sell Thermo Fisher custom-made EASY-Spray™ transfer lines, in combo sets with PharmaFluidics

' own line of µPAC™ chromatography micro-Chips, to constitute an ultra-high-resolution front-end source platform for Thermo Fisher mass spectrometry (MS) instruments.

     (Logo: )

"This is an exciting opportunity to facilitate our µPAC™ customers' proteome analysis workflows and raise their protein identification performance capabilities to new heights," said Katrien Vanhonacker, Vice President Business Development at PharmaFluidics. "It will provide all users of Thermo Scientific™ EASY-Spray™ source-equipped mass spectrometers with familiar access and connections to PharmaFluidics' separation chip."

"Today's bio-analytical customers require robust and easy-to-handle tools, to achieve new levels of performance in HPLC/MS," said Dr. Sven Klingel, Director Business Development Life Sciences Business Unit, Thermo Fisher. "Our custom-made EASY-Spray™ transfer lines facilitate coupling of µPAC™ columns to our HRAM MS detectors in a simple and easy to use way. As a result of this collaboration, our customers can enhance their separation options with a range of chip based ultra-high-resolution separations and best in class MS instruments to achieve high-quality results."

The µPAC™ Pillar Array Chromatography technology is an innovative platform that provides high-quality separation capabilities for MS. Using propietary micro-Chip microfluidic technology, the µPAC™ achieves superior separation of components in complex biological samples, improving LC-MS analysis results. The combined capabilities are revolutionizing the analysis of biological samples, allowing researchers, developers and vendors to keep pace in the buoyant and emerging fields of proteomics and protein-based diagnostics.

About PharmaFluidics

PharmaFluidics develops and commercializes its unique µPACTM range of micro-Chip based chromatography columns for use in biomarker, diagnostics and drug research & development applications in the global biotech and pharma industries. The unprecedented, game-changing sensitivity and separation performance of PharmaFluidics' µPACTM chromatography columns allows to identify substantially more compounds in complex biological samples, such as biopsies, proteome digests, culture media or bio-pharmaceutical actives.

The key expertise and IP estate of PharmaFluidics are the design, lithographic production, and surface treatment of silicon wafers for use as separation devices in liquid chromatography. PharmaFluidics collaborates with an extensive network of centers of excellence, pioneer users and global Mass Spectrometry instrument providers to develop an increasing range of applications.

For more information, please visit


Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands - Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services - we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services.

For more information, please visit

SOURCE PharmaFluidics

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store